N/A N=289 CYP2D6 Polymorphism in Patients of General Practice in Austria
Disorder Due Cytochrome P450 CYP2D6 Variant
Primary: Frequency of Metabolizer Status (PM, IM, NM, UM) in Patients — 233; 22; 21; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=78 CYP2B6 Polymorphisms in Methadone Disposition
Healthy Volunteers
Primary: Methadone Metabolism — 0.082; 0.073; 0.054 ratio — p=<0.05
N/A N=30 CYP2B6 Polymorphisms in Ketamine
Healthy Volunteers
Primary: The Effects of CYP2B6 Genetic Variants on Ketamine Metabolism and Clearance by CYP2B6*6 Hetero or Homozygote Genotype. — 29; 21; 26; 19 ng/ml*hr — p=<0.05
N/A N=293 Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia
Labor Pain · Post-cesarean Delivery
Primary: Duration of Intrathecal Fentanyl Analgesia — 70; 63 Minutes — p=0.54
Phase 4 N=105 Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery
Pain · Other Surgical Procedures · Impacted Third Molar Tooth
Primary: Score of Pain Measured by Visual Analogue Scale — 25 score on a scale (mm)
N/A N=176 Impact of CYP3A4*1G Polymorphism on Metabolism of Fentanyl in Chinese Patients Undergoing Lower Abdominal Surgery
Pain · Surgery
Primary: CYP3A4*1G Polymorphism — 103; 66; 7 participants
Phase 2 N=50 Clopidogrel Pharmacogenomics Project
Disease Susceptibility
Primary: Clopidogrel Resistance, Defined by P2Y12 Reaction Units (PRU)Value >230 — 30; 18 Number of Patients with PRU>230 — p==0.02
Phase 1 N=16 A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
Advanced Malignant Solid Tumors
Primary: Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) For Dextromethorphan and Dextrorphan 3 Days Prior to PF-00299804 Dosing — 206.4; 2199…
N/A N=13 Influence of CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of Bosentan
Drug Interactions
Primary: AUC of Bosentan — 9540; 5710; 5020 h*ng/ml
Phase 4 N=70 CYP2B6 Genetics and Drug Interactions in Healthy Volunteers
Healthy
Primary: Efavirenz AUC0-inf (Single Dose) and AUC0-24(Multiple Dose) — 411.53; 620.36; 522.42; 183.97 h*uM
N/A N=73 Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics
HIV
Primary: Effect of CYP2B6 Genotype on Efavirenz Clearance — 93.35; 76.08; 51.03; 50.05 ml/h/kg
N/A N=348 Emergency Department (ED) Drug Interaction in Emergency Department Patients
Drug Interactions
Primary: Difference in Clinically Significant Visual Analogue Scale for Pain and Nausea Change Between CYP2D6 Users and Non-users — 7.4; 10.9; -14.0 millimeters
Phase 4 N=14 Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study
Coronary Artery Disease
Primary: P2Y12 Reaction Unit (PRU) — 5; 24 PRU — p=<0.05
Phase 4 N=33 Effects of Isotretinoin on CYP2D6 Activity
CYP2D6 Polymorphism
Primary: CYP2D6 Activity as Measured by the Molar Concentration Ratio of Dextromethorphan (DM)/Dextrophan (DX) — 16.0; 12.5 Ratio
N/A N=16 Influence of OATP1B1 and CYP2C9 Genotypes on the Pharmacokinetics of Bosentan Before and During Clarithromycin
Drug Interactions
Primary: AUC — 11900; 6830; 25500 h*ng/ml
N/A N=21 Buprenorphine Disposition and CYP3A
Healthy
Primary: Plasma Cmax of Buprenorphine
Phase 4 N=23 Genetic Basis for Variation in the Renal Elimination of Metformin
Other Conditions That May Be A Focus of Clinical Attention
Primary: Renal Clearance of Metformin — 614; 441 mL/min
Phase 1 N=105 CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
Hypogonadism
Primary: Percent Change in Bone Mineral Density (BMD) According to rs700518 Polymorphism in the CYP19A1 Gene — 3.69; 4.13; 3.82; 0.38 percent change — p=<0.05
Phase 4 N=92 Pharmacogenomics and Post-Operative Nausea and Vomiting
Postoperative Nausea
Primary: Episodes of Postoperative Nausea — 0; 16 episodes
N/A N=10 The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity
Drug-Drug Interaction · Healthy Volunteers
Primary: Lovastatin AUC in the Presence of Fluoxetine — 170; 180 nmol*hr/L — p=>0.05
Phase 2 N=97 A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans
Opioid Sensitivity · Individual Difference · Abuse Opioids
Primary: Self-report Visual Analog Ratings of HIGH — 7.2; 6.6; 4.5; 5.6 score on a scale — p=0.567
N/A N=121 Developmental Regulation of Proteins Responsible for Transforming Drugs in the Body
Healthy
Primary: Change in CYP2D6 Drug Metabolism Phenotype With Age — -1.974; -2.083; -2.162; -2.073 unitless ratio — p=0.035
N/A N=104 Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm
Depression · Anxiety
Primary: Number of Outpatient Visits — 13 units on a scale
Phase 4 N=20 Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects
Other Conditions That May Be A Focus of Clinical Attention
Primary: Area Under the Curve (AUC) of Blood Concentration-time of Metformin — 9,200; 7,700 hour * µg/L
Phase 4 N=65 A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:
Coronary Artery Disease
Primary: Platelet Reactivity — 36; 33 PRU
N/A N=20 Influence of Cytochrome CYP3A4-induction by St. John's Wort on the Steady State Pharmacokinetics of Ambrisentan
Drug Interactions
Primary: AUC of Ambrisentan — 3670; 3520; 2790 h*ng/ml
N/A N=25 Rapid Screening Phenotype Test To Evaluate CYP 2C19 Enzyme Activity Using Stable Isotope [13C]Pantoprazole
Healthy
Primary: DOBmax (Maximum Value of DOB) — 4.44; 3.49; 0.92 ratio
N/A N=38 Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
Atrial Fibrillation
Primary: Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise — -10; -13 beats per minute
Phase 2 N=87 Naltrexone for Individuals of East Asian Descent
Alcohol Use Disorder
Primary: Subjective Response - Craving for Alcohol — 1.7037; 1.9965; 2.1012; 1.8478 score on a scale — p=0.39
Phase 1 N=22 Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs
Drug-Interactions
Primary: Losartan Area Under the Curve (AUC) in Plasma — 164; 185; 289 h*ng/mL